



Bocaliner™ Two-Stage Licensing Framework

Evaluate First. License with Confidence.

Overview

Bocaliner™ is a patented, FDA-registered oral device developed to address **oral mucositis and related oral health conditions**. Clinical studies and patient feedback demonstrate benefits including reduced oral pain, improved comfort, and better nutritional support during cancer treatment.

To reduce partner risk and accelerate adoption, licensing follows a **simple two-stage model**: evaluate the IP first, then license with confidence.

Stage 1: Evaluation License (90 Days)

The evaluation stage allows potential partners to validate **clinical relevance and commercial viability** before making a long-term commitment.

During the 90-day evaluation period, partners may:

- Validate IP effectiveness in real-world or pilot settings
- Assess patient and clinician acceptance
- Evaluate market demand and portfolio fit
- Limited, non-exclusive evaluation rights
- Access to clinical data and IP documentation

At the conclusion of the evaluation period, both parties determine whether to proceed based on data and strategic alignment.

Stage 2: Commercial License

Following a successful evaluation, partners may enter a full commercial license structured for scalable growth.

- **No upfront license fee**
- **Royalty-based economics** tied directly to revenues
- Territory, field of use, exclusivity, and milestones negotiated post-evaluation

IP Scope & Market Potential

Patent coverage includes oral mucositis, xerostomia (dry mouth), oral GVHD, recurrent oral ulcers, and sublingual drug delivery, enabling **multi-market expansion from a single platform**.

Next Step

A brief **15-minute discussion** to determine evaluation fit and outline a 90-day evaluation plan.

Contact

Rand Brenner

CEO, Licensing Consulting Group

www.licensingconsultinggroup.com